Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 896.

https://doi.org/10.1182/blood-2024-197929

Published: 2024

Journal Articles

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Blood (2024) 144 (Supplement 1): 7832.

https://doi.org/10.1182/blood-2024-204276

Published: 2024

Journal Articles

Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy

Ziad Abuhelwa, Fnu Amisha, Wenyi Fan, Gabriel De Avila, Doris K. Hansen, Ariel F. Grajales-Cruz, Brandon Blue, Omar Castaneda, Hien Liu, Ciara Louise Freeman, Taiga Nishihori, Frederick Locke, Kenneth H. Shain, Rachid Baz, Melissa Alsina

Blood (2024) 144 (Supplement 1): 4692.

https://doi.org/10.1182/blood-2024-204270

Published: 2024

Journal Articles

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2024-199278

Published: 2024

Journal Articles

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3784.

https://doi.org/10.1182/blood-2024-204232

Published: 2024

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Blood (2024) 144 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2024-206353

Published: 2024

Journal Articles

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2023-184406

Published: 2023

Journal Articles

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2023-187237

Published: 2023

Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2023) 142 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2023-174506

Published: 2023

Journal Articles

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Blood (2023) 142 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2023-185930

Published: 2023

Journal Articles

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Blood (2023) 142 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2023-173812

Published: 2023

Journal Articles

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Ning Dong, Hailing Zhang, Jinming Song, Jamila Mammadova, Bijal D. Shah, Hayder Saeed, Ariel F. Grajales-Cruz, Leidy Lismeris Isenalumhe, Sameh Gaballa, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz, Julio C Chavez

Blood (2023) 142 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2023-184779

Published: 2023

Journal Articles

Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Ariel F. Grajales-Cruz, Omar Castaneda, Doris K. Hansen, Mariola A Vazquez-Martinez, Brandon Blue, Sushmita Khadka, Hien Liu, Jose L. Ochoa-Bayona, Ciara Louise L. Freeman, Frederick L. Locke, Taiga Nishihori, Kenneth Shain, Rachid Baz, Melissa Alsina

Blood (2023) 142 (Supplement 1): 3351.

https://doi.org/10.1182/blood-2023-184928

Published: 2023

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Rachid C. Baz, Jongphil Kim, Christine Sam, Brandon J. Blue, Sonila Toska, Aaron Collier, Jason Brayer, Ariel F Grajales-Cruz, Melissa Alsina, Ariosto Siqueira Silva, Kenneth H. Shain

Blood (2022) 140 (Supplement 1): 7313–7314.

https://doi.org/10.1182/blood-2022-159164

Published: 2022

Journal Articles

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Taiga Nishihori, Ciara L. Freeman, Doris K. Hansen, Brandon J. Blue, Omar Alexis Castaneda Puglianini, Jongphil Kim, Ariel F. Grajales-Cruz, Jason Brayer, Jose Ochoa, Hien D. Liu, Kenneth H. Shain, Rachid C. Baz, Frederick L. Locke, Melissa Alsina

Blood (2022) 140 (Supplement 1): 4856–4858.

https://doi.org/10.1182/blood-2022-168888

Published: 2022

Journal Articles

Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Blood (2022) 140 (Supplement 1): 4688–4690.

https://doi.org/10.1182/blood-2022-168071

Published: 2022

Journal Articles

High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Ricardo Villanueva, Doris K. Hansen, Rolf Petter Tonseth, Kenneth L Gage, Zhouping Wei, Gabriel De Avila, Rachid C. Baz, Ariel F Grajales-Cruz, Omar Castaneda-Puglianini, Brandon J. Blue, Jason Brayer, Kenneth H. Shain, Melissa Alsina, Hien D. Liu, Taiga Nishihori, Meghan A Menges, Frederick L. Locke, Yoganand Balagurunathan, Ciara L. Freeman

Blood (2022) 140 (Supplement 1): 10402–10404.

https://doi.org/10.1182/blood-2022-167804

Published: 2022

Journal Articles

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Omar Alexis Castaneda Puglianini, Lauren C. Peres, Doris K. Hansen, Taiga Nishihori, Ariel F Grajales-Cruz, Brandon J. Blue, Jason Brayer, Ciara L. Freeman, Kenneth H. Shain, Hien D. Liu, Jose Ochoa, Frederick L. Locke, Rachid C. Baz, Melissa Alsina

Blood (2022) 140 (Supplement 1): 7538–7539.

https://doi.org/10.1182/blood-2022-170135

Published: 2022

Journal Articles

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2022) 140 (Supplement 1): 12778–12780.

https://doi.org/10.1182/blood-2022-158080

Published: 2022

Journal Articles

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, Doris K. Hansen, Hien D. Liu, Omar Alexis Castaneda Puglianini, Ciara L. Freeman, Brandon J. Blue, Jason Brayer, Jongphil Kim, Ariel F Grajales-Cruz, Jose Ochoa, Rachid C. Baz, Kenneth H. Shain, Frederick L. Locke, Melissa Alsina

Blood (2022) 140 (Supplement 1): 5174–5176.

https://doi.org/10.1182/blood-2022-171117

Published: 2022

NARROW

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only